nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—HSP90AA1—hematologic cancer	0.629	1	CbGaD
Nedocromil—CYSLTR2—hematopoietic system—hematologic cancer	0.00784	0.103	CbGeAlD
Nedocromil—FPR1—hematopoietic system—hematologic cancer	0.00706	0.0928	CbGeAlD
Nedocromil—PTGDR—hematopoietic system—hematologic cancer	0.00667	0.0876	CbGeAlD
Nedocromil—FPR1—blood—hematologic cancer	0.00468	0.0615	CbGeAlD
Nedocromil—CYSLTR2—lung—hematologic cancer	0.00455	0.0599	CbGeAlD
Nedocromil—FPR1—bone marrow—hematologic cancer	0.00453	0.0595	CbGeAlD
Nedocromil—PTGDR—blood—hematologic cancer	0.00442	0.0581	CbGeAlD
Nedocromil—PTGDR—bone marrow—hematologic cancer	0.00427	0.0562	CbGeAlD
Nedocromil—FPR1—lung—hematologic cancer	0.0041	0.0539	CbGeAlD
Nedocromil—PTGDR—lung—hematologic cancer	0.00387	0.0509	CbGeAlD
Nedocromil—CYSLTR1—hematopoietic system—hematologic cancer	0.00295	0.0388	CbGeAlD
Nedocromil—PTGDR—lymph node—hematologic cancer	0.00265	0.0348	CbGeAlD
Nedocromil—HSP90AA1—hematopoietic system—hematologic cancer	0.00256	0.0337	CbGeAlD
Nedocromil—CYSLTR1—blood—hematologic cancer	0.00196	0.0257	CbGeAlD
Nedocromil—HSP90AA1—gonad—hematologic cancer	0.00195	0.0256	CbGeAlD
Nedocromil—CYSLTR1—bone marrow—hematologic cancer	0.00189	0.0249	CbGeAlD
Nedocromil—HSP90AA1—Gemcitabine—Cytarabine—hematologic cancer	0.00178	1	CbGdCrCtD
Nedocromil—CYSLTR1—lung—hematologic cancer	0.00171	0.0225	CbGeAlD
Nedocromil—HSP90AA1—blood—hematologic cancer	0.0017	0.0223	CbGeAlD
Nedocromil—HSP90AA1—bone marrow—hematologic cancer	0.00164	0.0216	CbGeAlD
Nedocromil—HSP90AA1—lung—hematologic cancer	0.00149	0.0196	CbGeAlD
Nedocromil—HSP90AA1—testis—hematologic cancer	0.0014	0.0185	CbGeAlD
Nedocromil—CYSLTR1—lymph node—hematologic cancer	0.00117	0.0154	CbGeAlD
Nedocromil—HSP90AA1—lymph node—hematologic cancer	0.00102	0.0134	CbGeAlD
Nedocromil—Dyspnoea—Etoposide—hematologic cancer	6.46e-05	0.000455	CcSEcCtD
Nedocromil—Dizziness—Thalidomide—hematologic cancer	6.45e-05	0.000454	CcSEcCtD
Nedocromil—Nausea—Bortezomib—hematologic cancer	6.42e-05	0.000452	CcSEcCtD
Nedocromil—Hypersensitivity—Mitoxantrone—hematologic cancer	6.42e-05	0.000452	CcSEcCtD
Nedocromil—Hypersensitivity—Irinotecan—hematologic cancer	6.42e-05	0.000452	CcSEcCtD
Nedocromil—Asthenia—Vincristine—hematologic cancer	6.42e-05	0.000452	CcSEcCtD
Nedocromil—Vomiting—Thiotepa—hematologic cancer	6.41e-05	0.000452	CcSEcCtD
Nedocromil—Diarrhoea—Carmustine—hematologic cancer	6.41e-05	0.000451	CcSEcCtD
Nedocromil—Pneumonia—Epirubicin—hematologic cancer	6.4e-05	0.000451	CcSEcCtD
Nedocromil—Nausea—Bleomycin—hematologic cancer	6.38e-05	0.000449	CcSEcCtD
Nedocromil—Rash—Thiotepa—hematologic cancer	6.36e-05	0.000448	CcSEcCtD
Nedocromil—Bronchitis—Doxorubicin—hematologic cancer	6.35e-05	0.000447	CcSEcCtD
Nedocromil—Dermatitis—Thiotepa—hematologic cancer	6.35e-05	0.000447	CcSEcCtD
Nedocromil—Diarrhoea—Alitretinoin—hematologic cancer	6.35e-05	0.000447	CcSEcCtD
Nedocromil—Headache—Thiotepa—hematologic cancer	6.32e-05	0.000445	CcSEcCtD
Nedocromil—Diarrhoea—Ifosfamide—hematologic cancer	6.28e-05	0.000442	CcSEcCtD
Nedocromil—Nausea—Vinorelbine—hematologic cancer	6.27e-05	0.000442	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Etoposide—hematologic cancer	6.25e-05	0.00044	CcSEcCtD
Nedocromil—Body temperature increased—Cisplatin—hematologic cancer	6.25e-05	0.00044	CcSEcCtD
Nedocromil—Asthenia—Mitoxantrone—hematologic cancer	6.25e-05	0.00044	CcSEcCtD
Nedocromil—Asthenia—Irinotecan—hematologic cancer	6.25e-05	0.00044	CcSEcCtD
Nedocromil—Fatigue—Etoposide—hematologic cancer	6.25e-05	0.00044	CcSEcCtD
Nedocromil—Vomiting—Thalidomide—hematologic cancer	6.2e-05	0.000437	CcSEcCtD
Nedocromil—Dizziness—Carmustine—hematologic cancer	6.2e-05	0.000436	CcSEcCtD
Nedocromil—Pain—Etoposide—hematologic cancer	6.2e-05	0.000436	CcSEcCtD
Nedocromil—Conjunctivitis—Epirubicin—hematologic cancer	6.19e-05	0.000436	CcSEcCtD
Nedocromil—Rash—Thalidomide—hematologic cancer	6.15e-05	0.000433	CcSEcCtD
Nedocromil—Dermatitis—Thalidomide—hematologic cancer	6.15e-05	0.000433	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Doxorubicin—hematologic cancer	6.14e-05	0.000432	CcSEcCtD
Nedocromil—Dizziness—Alitretinoin—hematologic cancer	6.14e-05	0.000432	CcSEcCtD
Nedocromil—Diarrhoea—Vincristine—hematologic cancer	6.12e-05	0.000431	CcSEcCtD
Nedocromil—Headache—Thalidomide—hematologic cancer	6.11e-05	0.00043	CcSEcCtD
Nedocromil—Pain—Prednisolone—hematologic cancer	6.11e-05	0.00043	CcSEcCtD
Nedocromil—Asthenia—Gemcitabine—hematologic cancer	6.09e-05	0.000429	CcSEcCtD
Nedocromil—Dizziness—Ifosfamide—hematologic cancer	6.07e-05	0.000427	CcSEcCtD
Nedocromil—Pharyngitis—Methotrexate—hematologic cancer	6.06e-05	0.000427	CcSEcCtD
Nedocromil—Nausea—Thiotepa—hematologic cancer	5.99e-05	0.000422	CcSEcCtD
Nedocromil—Sinusitis—Epirubicin—hematologic cancer	5.97e-05	0.000421	CcSEcCtD
Nedocromil—Anaphylactic shock—Betamethasone—hematologic cancer	5.96e-05	0.00042	CcSEcCtD
Nedocromil—Anaphylactic shock—Dexamethasone—hematologic cancer	5.96e-05	0.00042	CcSEcCtD
Nedocromil—Diarrhoea—Mitoxantrone—hematologic cancer	5.96e-05	0.00042	CcSEcCtD
Nedocromil—Diarrhoea—Irinotecan—hematologic cancer	5.96e-05	0.00042	CcSEcCtD
Nedocromil—Vomiting—Carmustine—hematologic cancer	5.96e-05	0.000419	CcSEcCtD
Nedocromil—Pneumonia—Doxorubicin—hematologic cancer	5.93e-05	0.000417	CcSEcCtD
Nedocromil—Gastrointestinal pain—Etoposide—hematologic cancer	5.92e-05	0.000417	CcSEcCtD
Nedocromil—Dizziness—Vincristine—hematologic cancer	5.91e-05	0.000416	CcSEcCtD
Nedocromil—Rash—Carmustine—hematologic cancer	5.91e-05	0.000416	CcSEcCtD
Nedocromil—Dermatitis—Carmustine—hematologic cancer	5.9e-05	0.000416	CcSEcCtD
Nedocromil—Vomiting—Alitretinoin—hematologic cancer	5.9e-05	0.000416	CcSEcCtD
Nedocromil—Visual impairment—Methotrexate—hematologic cancer	5.89e-05	0.000414	CcSEcCtD
Nedocromil—Headache—Carmustine—hematologic cancer	5.87e-05	0.000413	CcSEcCtD
Nedocromil—Dyspnoea—Triamcinolone—hematologic cancer	5.86e-05	0.000413	CcSEcCtD
Nedocromil—Rash—Alitretinoin—hematologic cancer	5.85e-05	0.000412	CcSEcCtD
Nedocromil—Dermatitis—Alitretinoin—hematologic cancer	5.85e-05	0.000412	CcSEcCtD
Nedocromil—Vomiting—Ifosfamide—hematologic cancer	5.83e-05	0.000411	CcSEcCtD
Nedocromil—Hypersensitivity—Cisplatin—hematologic cancer	5.83e-05	0.00041	CcSEcCtD
Nedocromil—Headache—Alitretinoin—hematologic cancer	5.81e-05	0.000409	CcSEcCtD
Nedocromil—Diarrhoea—Gemcitabine—hematologic cancer	5.81e-05	0.000409	CcSEcCtD
Nedocromil—Nausea—Thalidomide—hematologic cancer	5.79e-05	0.000408	CcSEcCtD
Nedocromil—Dyspepsia—Triamcinolone—hematologic cancer	5.78e-05	0.000407	CcSEcCtD
Nedocromil—Rash—Ifosfamide—hematologic cancer	5.78e-05	0.000407	CcSEcCtD
Nedocromil—Dermatitis—Ifosfamide—hematologic cancer	5.78e-05	0.000407	CcSEcCtD
Nedocromil—Dizziness—Irinotecan—hematologic cancer	5.76e-05	0.000406	CcSEcCtD
Nedocromil—Urticaria—Etoposide—hematologic cancer	5.76e-05	0.000405	CcSEcCtD
Nedocromil—Rhinitis—Epirubicin—hematologic cancer	5.73e-05	0.000403	CcSEcCtD
Nedocromil—Abdominal pain—Etoposide—hematologic cancer	5.73e-05	0.000403	CcSEcCtD
Nedocromil—Body temperature increased—Etoposide—hematologic cancer	5.73e-05	0.000403	CcSEcCtD
Nedocromil—Conjunctivitis—Doxorubicin—hematologic cancer	5.73e-05	0.000403	CcSEcCtD
Nedocromil—Vomiting—Vincristine—hematologic cancer	5.69e-05	0.0004	CcSEcCtD
Nedocromil—Urticaria—Prednisolone—hematologic cancer	5.68e-05	0.0004	CcSEcCtD
Nedocromil—Asthenia—Cisplatin—hematologic cancer	5.67e-05	0.000399	CcSEcCtD
Nedocromil—Pharyngitis—Epirubicin—hematologic cancer	5.67e-05	0.000399	CcSEcCtD
Nedocromil—Fatigue—Triamcinolone—hematologic cancer	5.67e-05	0.000399	CcSEcCtD
Nedocromil—Rash—Vincristine—hematologic cancer	5.64e-05	0.000397	CcSEcCtD
Nedocromil—Dermatitis—Vincristine—hematologic cancer	5.63e-05	0.000397	CcSEcCtD
Nedocromil—Pain—Triamcinolone—hematologic cancer	5.62e-05	0.000396	CcSEcCtD
Nedocromil—Headache—Vincristine—hematologic cancer	5.6e-05	0.000394	CcSEcCtD
Nedocromil—Nausea—Carmustine—hematologic cancer	5.57e-05	0.000392	CcSEcCtD
Nedocromil—Vomiting—Mitoxantrone—hematologic cancer	5.54e-05	0.00039	CcSEcCtD
Nedocromil—Vomiting—Irinotecan—hematologic cancer	5.54e-05	0.00039	CcSEcCtD
Nedocromil—Sinusitis—Doxorubicin—hematologic cancer	5.53e-05	0.000389	CcSEcCtD
Nedocromil—Nausea—Alitretinoin—hematologic cancer	5.51e-05	0.000388	CcSEcCtD
Nedocromil—Visual impairment—Epirubicin—hematologic cancer	5.51e-05	0.000388	CcSEcCtD
Nedocromil—Rash—Mitoxantrone—hematologic cancer	5.49e-05	0.000387	CcSEcCtD
Nedocromil—Rash—Irinotecan—hematologic cancer	5.49e-05	0.000387	CcSEcCtD
Nedocromil—Dermatitis—Mitoxantrone—hematologic cancer	5.49e-05	0.000386	CcSEcCtD
Nedocromil—Dermatitis—Irinotecan—hematologic cancer	5.49e-05	0.000386	CcSEcCtD
Nedocromil—Headache—Mitoxantrone—hematologic cancer	5.46e-05	0.000384	CcSEcCtD
Nedocromil—Headache—Irinotecan—hematologic cancer	5.46e-05	0.000384	CcSEcCtD
Nedocromil—Nausea—Ifosfamide—hematologic cancer	5.45e-05	0.000384	CcSEcCtD
Nedocromil—Diarrhoea—Cisplatin—hematologic cancer	5.41e-05	0.000381	CcSEcCtD
Nedocromil—Vomiting—Gemcitabine—hematologic cancer	5.39e-05	0.00038	CcSEcCtD
Nedocromil—Rash—Gemcitabine—hematologic cancer	5.35e-05	0.000377	CcSEcCtD
Nedocromil—Dermatitis—Gemcitabine—hematologic cancer	5.34e-05	0.000376	CcSEcCtD
Nedocromil—Hypersensitivity—Etoposide—hematologic cancer	5.34e-05	0.000376	CcSEcCtD
Nedocromil—Headache—Gemcitabine—hematologic cancer	5.32e-05	0.000374	CcSEcCtD
Nedocromil—Nausea—Vincristine—hematologic cancer	5.31e-05	0.000374	CcSEcCtD
Nedocromil—Rhinitis—Doxorubicin—hematologic cancer	5.3e-05	0.000373	CcSEcCtD
Nedocromil—Hypersensitivity—Prednisolone—hematologic cancer	5.26e-05	0.000371	CcSEcCtD
Nedocromil—Pharyngitis—Doxorubicin—hematologic cancer	5.25e-05	0.00037	CcSEcCtD
Nedocromil—Dyspepsia—Dexamethasone—hematologic cancer	5.25e-05	0.00037	CcSEcCtD
Nedocromil—Dyspepsia—Betamethasone—hematologic cancer	5.25e-05	0.00037	CcSEcCtD
Nedocromil—Urticaria—Triamcinolone—hematologic cancer	5.22e-05	0.000368	CcSEcCtD
Nedocromil—Dysgeusia—Methotrexate—hematologic cancer	5.21e-05	0.000367	CcSEcCtD
Nedocromil—Asthenia—Etoposide—hematologic cancer	5.2e-05	0.000366	CcSEcCtD
Nedocromil—Body temperature increased—Triamcinolone—hematologic cancer	5.19e-05	0.000366	CcSEcCtD
Nedocromil—Anaphylactic shock—Prednisone—hematologic cancer	5.19e-05	0.000366	CcSEcCtD
Nedocromil—Nausea—Mitoxantrone—hematologic cancer	5.17e-05	0.000364	CcSEcCtD
Nedocromil—Nausea—Irinotecan—hematologic cancer	5.17e-05	0.000364	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.15e-05	0.000362	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.15e-05	0.000362	CcSEcCtD
Nedocromil—Fatigue—Betamethasone—hematologic cancer	5.14e-05	0.000362	CcSEcCtD
Nedocromil—Fatigue—Dexamethasone—hematologic cancer	5.14e-05	0.000362	CcSEcCtD
Nedocromil—Pain—Dexamethasone—hematologic cancer	5.1e-05	0.000359	CcSEcCtD
Nedocromil—Pain—Betamethasone—hematologic cancer	5.1e-05	0.000359	CcSEcCtD
Nedocromil—Visual impairment—Doxorubicin—hematologic cancer	5.1e-05	0.000359	CcSEcCtD
Nedocromil—Nausea—Gemcitabine—hematologic cancer	5.04e-05	0.000355	CcSEcCtD
Nedocromil—Vomiting—Cisplatin—hematologic cancer	5.03e-05	0.000354	CcSEcCtD
Nedocromil—Rash—Cisplatin—hematologic cancer	4.99e-05	0.000351	CcSEcCtD
Nedocromil—Dermatitis—Cisplatin—hematologic cancer	4.98e-05	0.000351	CcSEcCtD
Nedocromil—Diarrhoea—Etoposide—hematologic cancer	4.96e-05	0.000349	CcSEcCtD
Nedocromil—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.88e-05	0.000343	CcSEcCtD
Nedocromil—Gastrointestinal pain—Betamethasone—hematologic cancer	4.88e-05	0.000343	CcSEcCtD
Nedocromil—Dysgeusia—Epirubicin—hematologic cancer	4.87e-05	0.000343	CcSEcCtD
Nedocromil—Hypersensitivity—Triamcinolone—hematologic cancer	4.84e-05	0.000341	CcSEcCtD
Nedocromil—Dizziness—Etoposide—hematologic cancer	4.79e-05	0.000337	CcSEcCtD
Nedocromil—Leukopenia—Methotrexate—hematologic cancer	4.76e-05	0.000335	CcSEcCtD
Nedocromil—Urticaria—Dexamethasone—hematologic cancer	4.74e-05	0.000334	CcSEcCtD
Nedocromil—Urticaria—Betamethasone—hematologic cancer	4.74e-05	0.000334	CcSEcCtD
Nedocromil—Dizziness—Prednisolone—hematologic cancer	4.73e-05	0.000333	CcSEcCtD
Nedocromil—Asthenia—Triamcinolone—hematologic cancer	4.71e-05	0.000332	CcSEcCtD
Nedocromil—Body temperature increased—Betamethasone—hematologic cancer	4.71e-05	0.000332	CcSEcCtD
Nedocromil—Abdominal pain—Betamethasone—hematologic cancer	4.71e-05	0.000332	CcSEcCtD
Nedocromil—Body temperature increased—Dexamethasone—hematologic cancer	4.71e-05	0.000332	CcSEcCtD
Nedocromil—Abdominal pain—Dexamethasone—hematologic cancer	4.71e-05	0.000332	CcSEcCtD
Nedocromil—Nausea—Cisplatin—hematologic cancer	4.7e-05	0.000331	CcSEcCtD
Nedocromil—Cough—Methotrexate—hematologic cancer	4.64e-05	0.000327	CcSEcCtD
Nedocromil—Vomiting—Etoposide—hematologic cancer	4.61e-05	0.000324	CcSEcCtD
Nedocromil—Dyspepsia—Prednisone—hematologic cancer	4.57e-05	0.000322	CcSEcCtD
Nedocromil—Rash—Etoposide—hematologic cancer	4.57e-05	0.000322	CcSEcCtD
Nedocromil—Dermatitis—Etoposide—hematologic cancer	4.56e-05	0.000321	CcSEcCtD
Nedocromil—Headache—Etoposide—hematologic cancer	4.54e-05	0.00032	CcSEcCtD
Nedocromil—Chest pain—Methotrexate—hematologic cancer	4.53e-05	0.000319	CcSEcCtD
Nedocromil—Dysgeusia—Doxorubicin—hematologic cancer	4.51e-05	0.000317	CcSEcCtD
Nedocromil—Rash—Prednisolone—hematologic cancer	4.51e-05	0.000317	CcSEcCtD
Nedocromil—Dermatitis—Prednisolone—hematologic cancer	4.5e-05	0.000317	CcSEcCtD
Nedocromil—Fatigue—Prednisone—hematologic cancer	4.48e-05	0.000315	CcSEcCtD
Nedocromil—Headache—Prednisolone—hematologic cancer	4.48e-05	0.000315	CcSEcCtD
Nedocromil—Leukopenia—Epirubicin—hematologic cancer	4.45e-05	0.000314	CcSEcCtD
Nedocromil—Dizziness—Triamcinolone—hematologic cancer	4.35e-05	0.000306	CcSEcCtD
Nedocromil—Cough—Epirubicin—hematologic cancer	4.34e-05	0.000306	CcSEcCtD
Nedocromil—Anaphylactic shock—Methotrexate—hematologic cancer	4.34e-05	0.000306	CcSEcCtD
Nedocromil—Nausea—Etoposide—hematologic cancer	4.3e-05	0.000303	CcSEcCtD
Nedocromil—Asthenia—Dexamethasone—hematologic cancer	4.28e-05	0.000301	CcSEcCtD
Nedocromil—Asthenia—Betamethasone—hematologic cancer	4.28e-05	0.000301	CcSEcCtD
Nedocromil—Gastrointestinal pain—Prednisone—hematologic cancer	4.25e-05	0.000299	CcSEcCtD
Nedocromil—Nausea—Prednisolone—hematologic cancer	4.24e-05	0.000299	CcSEcCtD
Nedocromil—Chest pain—Epirubicin—hematologic cancer	4.24e-05	0.000298	CcSEcCtD
Nedocromil—Vomiting—Triamcinolone—hematologic cancer	4.18e-05	0.000294	CcSEcCtD
Nedocromil—Rash—Triamcinolone—hematologic cancer	4.14e-05	0.000292	CcSEcCtD
Nedocromil—Dry mouth—Epirubicin—hematologic cancer	4.14e-05	0.000292	CcSEcCtD
Nedocromil—Dermatitis—Triamcinolone—hematologic cancer	4.14e-05	0.000291	CcSEcCtD
Nedocromil—Urticaria—Prednisone—hematologic cancer	4.13e-05	0.00029	CcSEcCtD
Nedocromil—Leukopenia—Doxorubicin—hematologic cancer	4.12e-05	0.00029	CcSEcCtD
Nedocromil—Headache—Triamcinolone—hematologic cancer	4.12e-05	0.00029	CcSEcCtD
Nedocromil—Abdominal pain—Prednisone—hematologic cancer	4.1e-05	0.000289	CcSEcCtD
Nedocromil—Body temperature increased—Prednisone—hematologic cancer	4.1e-05	0.000289	CcSEcCtD
Nedocromil—Diarrhoea—Dexamethasone—hematologic cancer	4.08e-05	0.000287	CcSEcCtD
Nedocromil—Diarrhoea—Betamethasone—hematologic cancer	4.08e-05	0.000287	CcSEcCtD
Nedocromil—Anaphylactic shock—Epirubicin—hematologic cancer	4.06e-05	0.000286	CcSEcCtD
Nedocromil—Cough—Doxorubicin—hematologic cancer	4.02e-05	0.000283	CcSEcCtD
Nedocromil—Dizziness—Dexamethasone—hematologic cancer	3.94e-05	0.000278	CcSEcCtD
Nedocromil—Dizziness—Betamethasone—hematologic cancer	3.94e-05	0.000278	CcSEcCtD
Nedocromil—Chest pain—Doxorubicin—hematologic cancer	3.92e-05	0.000276	CcSEcCtD
Nedocromil—Nausea—Triamcinolone—hematologic cancer	3.9e-05	0.000275	CcSEcCtD
Nedocromil—Dyspnoea—Methotrexate—hematologic cancer	3.87e-05	0.000272	CcSEcCtD
Nedocromil—Dry mouth—Doxorubicin—hematologic cancer	3.83e-05	0.00027	CcSEcCtD
Nedocromil—Hypersensitivity—Prednisone—hematologic cancer	3.83e-05	0.000269	CcSEcCtD
Nedocromil—Dyspepsia—Methotrexate—hematologic cancer	3.82e-05	0.000269	CcSEcCtD
Nedocromil—Vomiting—Dexamethasone—hematologic cancer	3.79e-05	0.000267	CcSEcCtD
Nedocromil—Vomiting—Betamethasone—hematologic cancer	3.79e-05	0.000267	CcSEcCtD
Nedocromil—Rash—Betamethasone—hematologic cancer	3.76e-05	0.000265	CcSEcCtD
Nedocromil—Rash—Dexamethasone—hematologic cancer	3.76e-05	0.000265	CcSEcCtD
Nedocromil—Anaphylactic shock—Doxorubicin—hematologic cancer	3.76e-05	0.000265	CcSEcCtD
Nedocromil—Dermatitis—Dexamethasone—hematologic cancer	3.76e-05	0.000264	CcSEcCtD
Nedocromil—Dermatitis—Betamethasone—hematologic cancer	3.76e-05	0.000264	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.75e-05	0.000264	CcSEcCtD
Nedocromil—Fatigue—Methotrexate—hematologic cancer	3.74e-05	0.000263	CcSEcCtD
Nedocromil—Headache—Betamethasone—hematologic cancer	3.74e-05	0.000263	CcSEcCtD
Nedocromil—Headache—Dexamethasone—hematologic cancer	3.74e-05	0.000263	CcSEcCtD
Nedocromil—Asthenia—Prednisone—hematologic cancer	3.73e-05	0.000262	CcSEcCtD
Nedocromil—Pain—Methotrexate—hematologic cancer	3.71e-05	0.000261	CcSEcCtD
Nedocromil—Dyspnoea—Epirubicin—hematologic cancer	3.62e-05	0.000255	CcSEcCtD
Nedocromil—Dyspepsia—Epirubicin—hematologic cancer	3.57e-05	0.000252	CcSEcCtD
Nedocromil—Diarrhoea—Prednisone—hematologic cancer	3.55e-05	0.00025	CcSEcCtD
Nedocromil—Gastrointestinal pain—Methotrexate—hematologic cancer	3.55e-05	0.00025	CcSEcCtD
Nedocromil—Nausea—Dexamethasone—hematologic cancer	3.54e-05	0.000249	CcSEcCtD
Nedocromil—Nausea—Betamethasone—hematologic cancer	3.54e-05	0.000249	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.51e-05	0.000247	CcSEcCtD
Nedocromil—Fatigue—Epirubicin—hematologic cancer	3.5e-05	0.000247	CcSEcCtD
Nedocromil—Pain—Epirubicin—hematologic cancer	3.47e-05	0.000245	CcSEcCtD
Nedocromil—Urticaria—Methotrexate—hematologic cancer	3.45e-05	0.000243	CcSEcCtD
Nedocromil—Dizziness—Prednisone—hematologic cancer	3.43e-05	0.000242	CcSEcCtD
Nedocromil—Abdominal pain—Methotrexate—hematologic cancer	3.43e-05	0.000242	CcSEcCtD
Nedocromil—Body temperature increased—Methotrexate—hematologic cancer	3.43e-05	0.000242	CcSEcCtD
Nedocromil—Dyspnoea—Doxorubicin—hematologic cancer	3.35e-05	0.000236	CcSEcCtD
Nedocromil—Gastrointestinal pain—Epirubicin—hematologic cancer	3.32e-05	0.000234	CcSEcCtD
Nedocromil—Dyspepsia—Doxorubicin—hematologic cancer	3.31e-05	0.000233	CcSEcCtD
Nedocromil—Vomiting—Prednisone—hematologic cancer	3.3e-05	0.000232	CcSEcCtD
Nedocromil—Rash—Prednisone—hematologic cancer	3.27e-05	0.000231	CcSEcCtD
Nedocromil—Dermatitis—Prednisone—hematologic cancer	3.27e-05	0.00023	CcSEcCtD
Nedocromil—Headache—Prednisone—hematologic cancer	3.25e-05	0.000229	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.24e-05	0.000228	CcSEcCtD
Nedocromil—Fatigue—Doxorubicin—hematologic cancer	3.24e-05	0.000228	CcSEcCtD
Nedocromil—Urticaria—Epirubicin—hematologic cancer	3.23e-05	0.000227	CcSEcCtD
Nedocromil—Pain—Doxorubicin—hematologic cancer	3.21e-05	0.000226	CcSEcCtD
Nedocromil—Abdominal pain—Epirubicin—hematologic cancer	3.21e-05	0.000226	CcSEcCtD
Nedocromil—Body temperature increased—Epirubicin—hematologic cancer	3.21e-05	0.000226	CcSEcCtD
Nedocromil—Hypersensitivity—Methotrexate—hematologic cancer	3.2e-05	0.000225	CcSEcCtD
Nedocromil—Asthenia—Methotrexate—hematologic cancer	3.11e-05	0.000219	CcSEcCtD
Nedocromil—Nausea—Prednisone—hematologic cancer	3.08e-05	0.000217	CcSEcCtD
Nedocromil—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.07e-05	0.000216	CcSEcCtD
Nedocromil—Hypersensitivity—Epirubicin—hematologic cancer	2.99e-05	0.000211	CcSEcCtD
Nedocromil—Urticaria—Doxorubicin—hematologic cancer	2.99e-05	0.00021	CcSEcCtD
Nedocromil—Abdominal pain—Doxorubicin—hematologic cancer	2.97e-05	0.000209	CcSEcCtD
Nedocromil—Body temperature increased—Doxorubicin—hematologic cancer	2.97e-05	0.000209	CcSEcCtD
Nedocromil—Diarrhoea—Methotrexate—hematologic cancer	2.97e-05	0.000209	CcSEcCtD
Nedocromil—Asthenia—Epirubicin—hematologic cancer	2.91e-05	0.000205	CcSEcCtD
Nedocromil—Dizziness—Methotrexate—hematologic cancer	2.87e-05	0.000202	CcSEcCtD
Nedocromil—Diarrhoea—Epirubicin—hematologic cancer	2.78e-05	0.000196	CcSEcCtD
Nedocromil—Hypersensitivity—Doxorubicin—hematologic cancer	2.77e-05	0.000195	CcSEcCtD
Nedocromil—Vomiting—Methotrexate—hematologic cancer	2.76e-05	0.000194	CcSEcCtD
Nedocromil—Rash—Methotrexate—hematologic cancer	2.74e-05	0.000193	CcSEcCtD
Nedocromil—Dermatitis—Methotrexate—hematologic cancer	2.73e-05	0.000192	CcSEcCtD
Nedocromil—Headache—Methotrexate—hematologic cancer	2.72e-05	0.000191	CcSEcCtD
Nedocromil—Asthenia—Doxorubicin—hematologic cancer	2.7e-05	0.00019	CcSEcCtD
Nedocromil—Dizziness—Epirubicin—hematologic cancer	2.69e-05	0.000189	CcSEcCtD
Nedocromil—Vomiting—Epirubicin—hematologic cancer	2.58e-05	0.000182	CcSEcCtD
Nedocromil—Nausea—Methotrexate—hematologic cancer	2.58e-05	0.000181	CcSEcCtD
Nedocromil—Diarrhoea—Doxorubicin—hematologic cancer	2.57e-05	0.000181	CcSEcCtD
Nedocromil—Rash—Epirubicin—hematologic cancer	2.56e-05	0.00018	CcSEcCtD
Nedocromil—Dermatitis—Epirubicin—hematologic cancer	2.56e-05	0.00018	CcSEcCtD
Nedocromil—Headache—Epirubicin—hematologic cancer	2.54e-05	0.000179	CcSEcCtD
Nedocromil—Dizziness—Doxorubicin—hematologic cancer	2.48e-05	0.000175	CcSEcCtD
Nedocromil—Nausea—Epirubicin—hematologic cancer	2.41e-05	0.00017	CcSEcCtD
Nedocromil—Vomiting—Doxorubicin—hematologic cancer	2.39e-05	0.000168	CcSEcCtD
Nedocromil—Rash—Doxorubicin—hematologic cancer	2.37e-05	0.000167	CcSEcCtD
Nedocromil—Dermatitis—Doxorubicin—hematologic cancer	2.37e-05	0.000167	CcSEcCtD
Nedocromil—Headache—Doxorubicin—hematologic cancer	2.35e-05	0.000166	CcSEcCtD
Nedocromil—Nausea—Doxorubicin—hematologic cancer	2.23e-05	0.000157	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—MAPK14—hematologic cancer	8.14e-06	5.4e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—MAPK3—hematologic cancer	8.14e-06	5.4e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MAPK3—hematologic cancer	8.13e-06	5.39e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—GRB2—hematologic cancer	8.08e-06	5.36e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PDGFA—hematologic cancer	8.06e-06	5.34e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—FOS—hematologic cancer	7.99e-06	5.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—BAD—hematologic cancer	7.99e-06	5.3e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ESR1—hematologic cancer	7.99e-06	5.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CREB1—hematologic cancer	7.98e-06	5.29e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—HRAS—hematologic cancer	7.97e-06	5.28e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KITLG—hematologic cancer	7.94e-06	5.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NOTCH1—hematologic cancer	7.92e-06	5.25e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MYC—hematologic cancer	7.91e-06	5.24e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—FN1—hematologic cancer	7.89e-06	5.23e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TGFB1—hematologic cancer	7.89e-06	5.23e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MAPK3—hematologic cancer	7.85e-06	5.21e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN1B—hematologic cancer	7.83e-06	5.19e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CASP8—hematologic cancer	7.81e-06	5.18e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NFKBIA—hematologic cancer	7.8e-06	5.17e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—BAD—hematologic cancer	7.8e-06	5.17e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL6R—hematologic cancer	7.78e-06	5.16e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CREBBP—hematologic cancer	7.77e-06	5.15e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STAT5A—hematologic cancer	7.76e-06	5.15e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CD80—hematologic cancer	7.75e-06	5.14e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—AKT1—hematologic cancer	7.75e-06	5.14e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KIT—hematologic cancer	7.74e-06	5.13e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NOTCH1—hematologic cancer	7.72e-06	5.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—MTHFR—hematologic cancer	7.72e-06	5.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN2B—hematologic cancer	7.7e-06	5.1e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CASP3—hematologic cancer	7.68e-06	5.09e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL2—hematologic cancer	7.67e-06	5.08e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MYC—hematologic cancer	7.64e-06	5.06e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—IL6—hematologic cancer	7.63e-06	5.06e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TGFB1—hematologic cancer	7.62e-06	5.05e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTPN11—hematologic cancer	7.6e-06	5.04e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CD80—hematologic cancer	7.57e-06	5.02e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CG—hematologic cancer	7.55e-06	5.01e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KIT—hematologic cancer	7.55e-06	5.01e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—NRAS—hematologic cancer	7.55e-06	5.01e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CCND1—hematologic cancer	7.47e-06	4.95e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—JUN—hematologic cancer	7.46e-06	4.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CD86—hematologic cancer	7.44e-06	4.94e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTPN11—hematologic cancer	7.42e-06	4.92e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAP2K1—hematologic cancer	7.42e-06	4.92e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CD—hematologic cancer	7.37e-06	4.89e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CREB1—hematologic cancer	7.37e-06	4.88e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HES1—hematologic cancer	7.34e-06	4.87e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—KRAS—hematologic cancer	7.32e-06	4.85e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—KRAS—hematologic cancer	7.31e-06	4.85e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NCOR1—hematologic cancer	7.3e-06	4.84e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—BRAF—hematologic cancer	7.28e-06	4.82e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—MAPK3—hematologic cancer	7.23e-06	4.79e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN1A—hematologic cancer	7.23e-06	4.79e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CSF2—hematologic cancer	7.22e-06	4.79e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGF1—hematologic cancer	7.22e-06	4.79e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PTEN—hematologic cancer	7.21e-06	4.78e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CREB1—hematologic cancer	7.19e-06	4.77e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IL6R—hematologic cancer	7.19e-06	4.77e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CREBBP—hematologic cancer	7.18e-06	4.76e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FOXO1—hematologic cancer	7.11e-06	4.72e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PDGFRB—hematologic cancer	7.1e-06	4.71e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—BRAF—hematologic cancer	7.1e-06	4.71e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—KRAS—hematologic cancer	7.06e-06	4.68e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MAPK8—hematologic cancer	7.06e-06	4.68e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—FGF2—hematologic cancer	7.06e-06	4.68e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—HRAS—hematologic cancer	7.04e-06	4.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—AKT1—hematologic cancer	7.04e-06	4.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCL2—hematologic cancer	7.03e-06	4.66e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL6R—hematologic cancer	7.01e-06	4.65e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CREBBP—hematologic cancer	7e-06	4.64e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PDGFRA—hematologic cancer	6.99e-06	4.63e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—JAK1—hematologic cancer	6.97e-06	4.62e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PRKCG—hematologic cancer	6.97e-06	4.62e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3R1—hematologic cancer	6.96e-06	4.61e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EP300—hematologic cancer	6.88e-06	4.56e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MAP2K1—hematologic cancer	6.85e-06	4.54e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TP53—hematologic cancer	6.82e-06	4.52e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CD—hematologic cancer	6.8e-06	4.51e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—JAK2—hematologic cancer	6.76e-06	4.48e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—IL6—hematologic cancer	6.74e-06	4.47e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PIK3CA—hematologic cancer	6.72e-06	4.46e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PIK3CA—hematologic cancer	6.72e-06	4.45e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—BCL2—hematologic cancer	6.7e-06	4.44e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SRC—hematologic cancer	6.69e-06	4.44e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAP2K1—hematologic cancer	6.68e-06	4.43e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IFNG—hematologic cancer	6.64e-06	4.4e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CD—hematologic cancer	6.64e-06	4.4e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MDM2—hematologic cancer	6.6e-06	4.38e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—PIK3CA—hematologic cancer	6.58e-06	4.36e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—VEGFA—hematologic cancer	6.52e-06	4.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—FGF2—hematologic cancer	6.52e-06	4.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL2RA—hematologic cancer	6.51e-06	4.31e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—KRAS—hematologic cancer	6.5e-06	4.31e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TP53—hematologic cancer	6.5e-06	4.31e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PIK3CA—hematologic cancer	6.49e-06	4.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CG—hematologic cancer	6.48e-06	4.3e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—STAT3—hematologic cancer	6.45e-06	4.28e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NRAS—hematologic cancer	6.44e-06	4.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TERT—hematologic cancer	6.43e-06	4.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3R1—hematologic cancer	6.43e-06	4.26e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CB—hematologic cancer	6.42e-06	4.26e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MTOR—hematologic cancer	6.42e-06	4.26e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CD4—hematologic cancer	6.41e-06	4.25e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—FGF2—hematologic cancer	6.36e-06	4.21e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PDGFB—hematologic cancer	6.28e-06	4.16e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TP53—hematologic cancer	6.27e-06	4.16e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3R1—hematologic cancer	6.27e-06	4.16e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—JAK2—hematologic cancer	6.24e-06	4.14e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—HRAS—hematologic cancer	6.22e-06	4.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—AKT1—hematologic cancer	6.22e-06	4.12e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—HRAS—hematologic cancer	6.21e-06	4.12e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MAPK3—hematologic cancer	6.16e-06	4.09e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TSC2—hematologic cancer	6.14e-06	4.07e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MDM2—hematologic cancer	6.1e-06	4.04e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—JAK2—hematologic cancer	6.09e-06	4.04e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDKN1B—hematologic cancer	6.03e-06	4e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CREBBP—hematologic cancer	6.01e-06	3.98e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—HRAS—hematologic cancer	6e-06	3.98e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MYC—hematologic cancer	5.99e-06	3.97e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TGFB1—hematologic cancer	5.98e-06	3.96e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PIK3CA—hematologic cancer	5.97e-06	3.96e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—IL6—hematologic cancer	5.95e-06	3.95e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MDM2—hematologic cancer	5.95e-06	3.94e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IL6—hematologic cancer	5.95e-06	3.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MTOR—hematologic cancer	5.93e-06	3.93e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CB—hematologic cancer	5.93e-06	3.93e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL1B—hematologic cancer	5.92e-06	3.93e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CD4—hematologic cancer	5.92e-06	3.92e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGFR3—hematologic cancer	5.9e-06	3.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL2—hematologic cancer	5.9e-06	3.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAPK14—hematologic cancer	5.85e-06	3.88e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CB—hematologic cancer	5.79e-06	3.84e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MTOR—hematologic cancer	5.79e-06	3.84e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IL6—hematologic cancer	5.74e-06	3.81e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—JUN—hematologic cancer	5.74e-06	3.8e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ESR1—hematologic cancer	5.73e-06	3.8e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CD—hematologic cancer	5.7e-06	3.78e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FN1—hematologic cancer	5.66e-06	3.76e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ALB—hematologic cancer	5.63e-06	3.73e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—BAD—hematologic cancer	5.6e-06	3.71e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NFKBIA—hematologic cancer	5.6e-06	3.71e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN1B—hematologic cancer	5.57e-06	3.69e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDKN1A—hematologic cancer	5.56e-06	3.69e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PTEN—hematologic cancer	5.55e-06	3.68e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NOTCH1—hematologic cancer	5.54e-06	3.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—KRAS—hematologic cancer	5.54e-06	3.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—HRAS—hematologic cancer	5.52e-06	3.66e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—AKT1—hematologic cancer	5.49e-06	3.64e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—AKT1—hematologic cancer	5.49e-06	3.64e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAPK8—hematologic cancer	5.43e-06	3.6e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN1B—hematologic cancer	5.43e-06	3.6e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CD80—hematologic cancer	5.43e-06	3.6e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KIT—hematologic cancer	5.42e-06	3.59e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CG—hematologic cancer	5.42e-06	3.59e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3R1—hematologic cancer	5.38e-06	3.57e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—AKT1—hematologic cancer	5.37e-06	3.56e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTPN11—hematologic cancer	5.33e-06	3.53e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CASP3—hematologic cancer	5.32e-06	3.53e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL2—hematologic cancer	5.31e-06	3.52e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—AKT1—hematologic cancer	5.3e-06	3.51e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EP300—hematologic cancer	5.29e-06	3.51e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—IL6—hematologic cancer	5.29e-06	3.51e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCND1—hematologic cancer	5.18e-06	3.43e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—JUN—hematologic cancer	5.17e-06	3.43e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CREB1—hematologic cancer	5.16e-06	3.42e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—SRC—hematologic cancer	5.15e-06	3.41e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN1A—hematologic cancer	5.14e-06	3.41e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTEN—hematologic cancer	5.13e-06	3.4e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—BRAF—hematologic cancer	5.1e-06	3.38e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CA—hematologic cancer	5.09e-06	3.37e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCL2—hematologic cancer	5.05e-06	3.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL6R—hematologic cancer	5.03e-06	3.34e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CREBBP—hematologic cancer	5.03e-06	3.33e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN1A—hematologic cancer	5.01e-06	3.32e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTEN—hematologic cancer	5e-06	3.31e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CB—hematologic cancer	4.97e-06	3.29e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—STAT3—hematologic cancer	4.96e-06	3.29e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—NRAS—hematologic cancer	4.95e-06	3.28e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TP53—hematologic cancer	4.92e-06	3.26e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAPK8—hematologic cancer	4.89e-06	3.24e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EP300—hematologic cancer	4.89e-06	3.24e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—AKT1—hematologic cancer	4.88e-06	3.23e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAP2K1—hematologic cancer	4.8e-06	3.18e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EP300—hematologic cancer	4.77e-06	3.16e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CD—hematologic cancer	4.77e-06	3.16e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SRC—hematologic cancer	4.75e-06	3.15e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAPK3—hematologic cancer	4.74e-06	3.14e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—HRAS—hematologic cancer	4.71e-06	3.12e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SRC—hematologic cancer	4.64e-06	3.07e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—STAT3—hematologic cancer	4.58e-06	3.04e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NRAS—hematologic cancer	4.57e-06	3.03e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGF2—hematologic cancer	4.56e-06	3.02e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—VEGFA—hematologic cancer	4.52e-06	2.99e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL6—hematologic cancer	4.51e-06	2.99e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3R1—hematologic cancer	4.5e-06	2.98e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—STAT3—hematologic cancer	4.47e-06	2.96e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NRAS—hematologic cancer	4.46e-06	2.96e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MAPK3—hematologic cancer	4.38e-06	2.9e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—JAK2—hematologic cancer	4.37e-06	2.9e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTEN—hematologic cancer	4.29e-06	2.85e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAPK3—hematologic cancer	4.27e-06	2.83e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MDM2—hematologic cancer	4.27e-06	2.83e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KRAS—hematologic cancer	4.26e-06	2.83e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MYC—hematologic cancer	4.26e-06	2.82e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TGFB1—hematologic cancer	4.25e-06	2.82e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—AKT1—hematologic cancer	4.16e-06	2.76e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MYC—hematologic cancer	4.16e-06	2.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MTOR—hematologic cancer	4.15e-06	2.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CB—hematologic cancer	4.15e-06	2.75e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TGFB1—hematologic cancer	4.15e-06	2.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—EP300—hematologic cancer	4.09e-06	2.71e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KRAS—hematologic cancer	3.94e-06	2.61e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CA—hematologic cancer	3.92e-06	2.6e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN1B—hematologic cancer	3.9e-06	2.58e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KRAS—hematologic cancer	3.84e-06	2.55e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CASP3—hematologic cancer	3.82e-06	2.53e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL2—hematologic cancer	3.81e-06	2.53e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCND1—hematologic cancer	3.72e-06	2.47e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—JUN—hematologic cancer	3.71e-06	2.46e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HRAS—hematologic cancer	3.62e-06	2.4e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CA—hematologic cancer	3.62e-06	2.4e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN1A—hematologic cancer	3.6e-06	2.38e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTEN—hematologic cancer	3.59e-06	2.38e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CA—hematologic cancer	3.53e-06	2.34e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAPK8—hematologic cancer	3.51e-06	2.33e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL6—hematologic cancer	3.47e-06	2.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EP300—hematologic cancer	3.42e-06	2.27e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TP53—hematologic cancer	3.41e-06	2.26e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HRAS—hematologic cancer	3.35e-06	2.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SRC—hematologic cancer	3.33e-06	2.21e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HRAS—hematologic cancer	3.26e-06	2.16e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—VEGFA—hematologic cancer	3.24e-06	2.15e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STAT3—hematologic cancer	3.21e-06	2.13e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NRAS—hematologic cancer	3.2e-06	2.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IL6—hematologic cancer	3.2e-06	2.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—AKT1—hematologic cancer	3.2e-06	2.12e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL6—hematologic cancer	3.12e-06	2.07e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAPK3—hematologic cancer	3.07e-06	2.03e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CA—hematologic cancer	3.03e-06	2.01e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MYC—hematologic cancer	2.98e-06	1.98e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TGFB1—hematologic cancer	2.98e-06	1.97e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—AKT1—hematologic cancer	2.95e-06	1.96e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKT1—hematologic cancer	2.88e-06	1.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KRAS—hematologic cancer	2.76e-06	1.83e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CA—hematologic cancer	2.53e-06	1.68e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—AKT1—hematologic cancer	2.47e-06	1.64e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TP53—hematologic cancer	2.45e-06	1.62e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HRAS—hematologic cancer	2.34e-06	1.55e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL6—hematologic cancer	2.24e-06	1.49e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKT1—hematologic cancer	2.07e-06	1.37e-05	CbGpPWpGaD
